{
    "clinical_study": {
        "@rank": "116206", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Interferon alfa may interfere with the growth of the cancer\n      cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It\n      is not yet known which treatment regimen is more effective in treating melanoma.\n\n      PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of\n      combination chemotherapy plus interferon alfa and interleukin-2 in treating patients who\n      have metastatic melanoma."
        }, 
        "brief_title": "Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma", 
        "condition": "Melanoma (Skin)", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Assess the rate of disease stabilization in patients with metastatic melanoma when\n           treated with interferon alfa, dacarbazine, cisplatin, and interleukin-2.\n\n        -  Assess toxicity, overall response rate, and response duration in these patients when\n           treated with this regimen.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      center. Patients are randomized to one of two treatment arms.\n\n        -  Arm I: Patients receive dacarbazine IV over 1 hour and cisplatin IV over 3 hours on\n           days 1-3. Patients also receive interferon alfa subcutaneously (SQ) on days 1-5 and\n           interleukin-2 by continuous IV infusion on days 4-9. Treatment continues every 28 days\n           for a maximum of 4 courses in the absence of disease progression or unacceptable\n           toxicity.\n\n        -  Arm II: Patients receive dacarbazine IV on day 1 and 22 every 28 days for 2 courses.\n           Patients then receive treatment as in arm I for a maximum of 4 courses.\n\n      Patients are followed every 2 months for 6 months, then every 3 months thereafter.\n\n      PROJECTED ACCRUAL: A total of 42-90 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed melanoma that is metastatic and unresectable\n\n          -  Measurable, progressive disease (by physical exam and/or noninvasive imaging)\n\n               -  No prior irradiation of indicator lesions\n\n          -  No CNS metastases (confirmed by CT or MRI)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 70\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Greater than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 2,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  No serious hepatic disease\n\n        Renal:\n\n          -  Creatinine no greater than 1.65 mg/dL\n\n          -  No serious renal disease\n\n        Cardiovascular:\n\n          -  No serious cardiac disease\n\n        Pulmonary:\n\n          -  No serious pulmonary disease\n\n        Other:\n\n          -  No organ allograft\n\n          -  No autoimmune disease\n\n          -  No uncontrolled infection\n\n          -  No active peptic ulcer\n\n          -  No hyper or hypothyroidism\n\n          -  No requirement for corticosteroids\n\n          -  No second malignancy except basal cell skin carcinoma or carcinoma in situ of the\n             cervix\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior immunotherapy with interleukin-2\n\n          -  No prior interferon alfa in combination with cisplatin or dacarbazine\n\n        Chemotherapy:\n\n          -  No prior chemotherapy with cisplatin in combination with dacarbazine\n\n          -  More than 3 months since prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Prior radiotherapy allowed\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002669", 
            "org_study_id": "EORTC-18951", 
            "secondary_id": "EORTC-18951"
        }, 
        "intervention": [
            {
                "intervention_name": "aldesleukin", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "recombinant interferon alfa", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "dacarbazine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Aldesleukin", 
                "Cisplatin", 
                "Dacarbazine"
            ]
        }, 
        "keyword": [
            "stage IV melanoma", 
            "recurrent melanoma"
        ], 
        "lastchanged_date": "June 29, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-18951"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "A-5020"
                    }, 
                    "name": "Landeskrankenanstalten - Salzburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "Hopital Universitaire Erasme"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels (Bruxelles)", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "B-2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25030"
                    }, 
                    "name": "CHR de Besancon - Hopital Saint-Jacques"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "CHU Pitie-Salpetriere"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-12200"
                    }, 
                    "name": "Universitaetsklinikum Benjamin Franklin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-10117"
                    }, 
                    "name": "Universitaetsklinikum Charite"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-13122"
                    }, 
                    "name": "Robert Roessle Klinik"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "D-22765"
                    }, 
                    "name": "Haematologisch-Onkologische Praxis Altona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "D-55101"
                    }, 
                    "name": "Johannes Gutenberg University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "zip": "D-68135"
                    }, 
                    "name": "III Medizinische Klinik Mannheim"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20141"
                    }, 
                    "name": "Istituto Europeo Di Oncologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "NL-6500 HB"
                    }, 
                    "name": "University Medical Center Nijmegen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Rotterdam Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal", 
                        "zip": "4200"
                    }, 
                    "name": "Instituto Portugues de Oncologia do Porto"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "Universitaetsspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "St. James's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Royal Marsden NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westcliff-On-Sea", 
                        "country": "United Kingdom", 
                        "state": "England"
                    }, 
                    "name": "Southend NHS Trust Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bournemouth", 
                        "country": "United Kingdom", 
                        "zip": "BH7 7DW"
                    }, 
                    "name": "Royal Bournemouth Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Portugal", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "official_title": "TREATMENT OF METASTATIC MELANOMA WITH DTIC, CDDP AND IFN ALPHA WITH OR WITHOUT IL-2: A RANDOMIZED PHASE III TRIAL", 
        "overall_official": {
            "affiliation": "Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin", 
            "last_name": "Ulrich Keilholz, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2002", 
            "@type": "Actual"
        }, 
        "reference": [
            {
                "PMID": "19419855", 
                "citation": "Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009 May 4; [Epub ahead of print]"
            }, 
            {
                "citation": "Keilholz U, Suciu S, Bedikian AY, et al.: LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: re-analysis of GM301 and EORTC18951 randomized trials. [Abstract] J Clin Oncol 25 (Suppl 18): A-8552, 485s, 2007."
            }, 
            {
                "PMID": "10685668", 
                "citation": "Keilholz U, Eggermont AM. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S99-103."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002669"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "17443000", 
                "citation": "Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007 Apr 20;25(12):1562-9."
            }, 
            {
                "PMID": "17023156", 
                "citation": "Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer. 2006 Nov;42(17):2991-5. Epub 2006 Oct 4."
            }, 
            {
                "PMID": "16170182", 
                "citation": "Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55."
            }, 
            {
                "citation": "Keilholz U, Punt CJ, Gore M, et al.: Dacarbazine, cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: interim analysis of EORTC trial 18951. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A2043, 530a, 1999."
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1995", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }, 
    "geocoordinates": {
        "CHR de Besancon - Hopital Saint-Jacques": "47.238 6.024", 
        "CHU Pitie-Salpetriere": "48.857 2.352", 
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "Centre Leon Berard": "45.764 4.836", 
        "Haematologisch-Onkologische Praxis Altona": "53.557 9.995", 
        "Hopital Universitaire Erasme": "50.85 4.352", 
        "III Medizinische Klinik Mannheim": "49.461 8.49", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Instituto Portugues de Oncologia do Porto": "41.15 -8.61", 
        "Istituto Europeo Di Oncologia": "45.464 9.188", 
        "Johannes Gutenberg University": "49.993 8.247", 
        "Landeskrankenanstalten - Salzburg": "47.809 13.055", 
        "Robert Roessle Klinik": "52.524 13.406", 
        "Rotterdam Cancer Institute": "51.924 4.482", 
        "Royal Bournemouth Hospital": "50.719 -1.881", 
        "Royal Marsden NHS Trust": "51.508 -0.128", 
        "Southend NHS Trust Hospital": "51.536 0.697", 
        "St. James's Hospital": "53.801 -1.549", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitaetsklinikum Benjamin Franklin": "52.524 13.406", 
        "Universitaetsklinikum Charite": "52.524 13.406", 
        "Universitaetsspital": "47.369 8.539", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438", 
        "University Medical Center Nijmegen": "51.843 5.855"
    }
}